bluebird bio Inc. (NASDAQ:BLUE) has a beta value of 0.95 and has seen 5.42 million shares traded in the last trading session. The company, currently valued at $490.00M, closed the last trade at $6.19 per share which meant it lost -$0.01 on the day or -0.16% during that session. The BLUE stock price is -38.61% off its 52-week high price of $8.58 and 53.63% above the 52-week low of $2.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.44 million shares traded. The 3-month trading volume is 3.78 million shares.
The consensus among analysts is that bluebird bio Inc. (BLUE) is a Hold stock at the moment, with a recommendation rating of 3.10. 2 analysts rate the stock as a Sell, while 1 rate it as Overweight. 8 out of 11 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$1.12.
bluebird bio Inc. (NASDAQ:BLUE) trade information
Sporting -0.16% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the BLUE stock price touched $6.19 or saw a rise of 20.44%. Year-to-date, bluebird bio Inc. shares have moved -10.55%, while the 5-day performance has seen it change -21.55%. Over the past 30 days, the shares of bluebird bio Inc. (NASDAQ:BLUE) have changed -16.58%. Short interest in the company has seen 22.44 million shares shorted with days to cover at 2.66.
Wall Street analysts have a consensus price target for the stock at $7.33, which means that the shares’ value could jump 15.55% from current levels. The projected low price target is $3.00 while the price target rests at a high of $10.00. In that case, then, we find that the current price level is -61.55% off the targeted high while a plunge would see the stock lose 51.53% from current levels.
bluebird bio Inc. (BLUE) estimates and forecasts
Figures show that bluebird bio Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 35.15% over the past 6 months, with this year growth rate of 44.53%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 64.60% and 79.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 392.60%.
7 analysts offering their estimates for the company have set an average revenue estimate of $1 million for the current quarter. 6 have an estimated revenue figure of $18.08 million for the next quarter concluding in Dec 2022. Year-ago sales stood $37.6 million and $1.61 million respectively for this quarter and the next, and analysts expect sales will shrink by -97.30% for the current quarter and 1,025.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.90% over the past 5 years. Earnings growth for 2023 is a modest 9.50% while over the next 5 years, the company’s earnings are expected to increase by 56.40%.
bluebird bio Inc. is expected to release its next earnings report between March 02 and March 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
bluebird bio Inc. (NASDAQ:BLUE)’s Major holders
Insiders own 1.17% of the company shares, while shares held by institutions stand at 82.20% with a share float percentage of 83.17%. Investors are also buoyed by the number of investors in a company, with bluebird bio Inc. having a total of 234 institutions that hold shares in the company. The top two institutional holders are Wellington Management Group, LLP with over 6.14 million shares worth more than $25.42 million. As of Jun 29, 2022, Wellington Management Group, LLP held 7.96% of shares outstanding.
The other major institutional holder is Tang Capital Management, LLC, with the holding of over 5.91 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $24.47 million and represent 7.66% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Specialized-Health Care Fund. As of Sep 29, 2022, the former fund manager holds about 13.70% shares in the company for having 10.56 million shares of worth $66.87 million while later fund manager owns 5.7 million shares of worth $23.08 million as of Jul 30, 2022, which makes it owner of about 7.39% of company’s outstanding stock.